BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company has as signed a binding letter of intent with Royal Emerald Pharmaceuticals. This company is only one of seven Drug Enforcement Administration bulk-manufacturing registration holders permitted to grow marijuana in the United States for drug-related studies. Sobel telling Proactive the partnership will run for 3 years and allows for unique and patentable cannabis compositions to be used for research into treatment of any number of conditions.
BioHarvest Sciences signs agreement with Royal Emerald Pharmaceuticals for cannabis research
